SHR3680 + digoxin + Rosuvastatin calcium + metformin hydrochloride
Phase 1UNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Drug-drug Interaction,SHR3680
Conditions
Drug-drug Interaction,SHR3680
Trial Timeline
Nov 19, 2020 → Jul 5, 2021
NCT ID
NCT04621669About SHR3680 + digoxin + Rosuvastatin calcium + metformin hydrochloride
SHR3680 + digoxin + Rosuvastatin calcium + metformin hydrochloride is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Drug-drug Interaction,SHR3680. The current trial status is unknown. This product is registered under clinical trial identifier NCT04621669. Target conditions include Drug-drug Interaction,SHR3680.
Hype Score Breakdown
Clinical
6
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04621669 | Phase 1 | UNKNOWN |
Competing Products
15 competing products in Drug-drug Interaction,SHR3680